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Abstract
Purpose To evaluate toxicity of radiochemotherapy
schedule using daily-low-dose-cisplatin in radiochemother-
apy of locally-advanced head-and-neck-cancer (HNSCC).
Methods and patients From October 2003 to October
2006, 50 patients with HNSCC (stage III/IVA/IVB) were
treated. In 32 patients, surgery and adjuvant radiotherapy
(64 Gy), in 18 patients deWnitive radiotherapy(70 Gy) was
performed. Low-dose-cisplatin was applied concomitantly
(6 mg/m2/every radiotherapy-day).
Results Acute toxicity ¸grade 3 was observed in 22
patients (11 patients mucositis/dysphagia, 7 hematologic
toxicity, 4 mucositis/dysphagia/hematologic toxicity). 90%
of our patients received >80% of the planned cumulative
chemotherapy dose, 94% the intended dose of radiotherapy.
After median follow-up of 24.2 months, 3-year overall sur-
vival and loco-regional control rates were 67.1 and 78%.
During follow-up, chronic toxicity ¸grade 3 (xerostomia,
subcutaneous  Wbrosis, or lymphedema) was observed in
nine patients.
Conclusion We found chemoradiation with daily-low-
dose-cisplatin to be feasible with advantage of low acute
and chronic toxicity. Therefore, use of low-dose-cisplatin
should be evaluated in future clinical trials.
Keywords Low dose cisplatin · HNSCC · 
Radiochemotherapy · Toxicity
Introduction
Radiotherapy is an important therapeutic modality in the
treatment of advanced (UICC stage III and IVA/IVB) head
neck squamous cell carcinoma (HNSCC) in curative intent
and is used either as adjuvant or primary treatment modality.
It has been proven that concomitant chemotherapy improves
overall survival as well as loco-regional control both in the
primary and in the adjuvant situation (Bauchaud et al. 1996;
Bernier et al. 2004; Browman et al. 2001; Cooper et al.
2004; El-Sayed and Nelson 1996; Pignon et al. 2000). How-
ever, concomitant chemotherapy also increases the risk of
escalated acute toxicity. The optimal chemotherapy regimen
has not been evaluated, yet. Common regimens besides sev-
eral others are cisplatin 100 mg/m2 on days 1, 22, and 43 of
radiotherapy (Rades et al. 2008); 40 mg/m2 weekly during
radiotherapy (Geeta et al. 2006), or 20 mg/m2 for 4 days in
week 1 and 5 of radiotherapy (Lau et al. 2006), optionally
combined with 5-FU (Adelstein et al. 2006). A relatively
infrequent used regimen in radiochemotherapy for head and
neck cancer is the use of daily low dose cisplatin, which
includes the administration of cisplatin 6 mg/m2 on each
radiotherapy day. However, this application form is well
established in the treatment of locally advanced non small
cell lung cancers with primary radiochemotherapy (Pradier
et al. 2005; Schaake-Koning et al. 1992; Semrau et al. 2007;
Takiguchi et al. 2005). The experiences obtained from these
studies regarding the treatment of NSCLC show that good
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treatment outcome with acceptable toxicity can be achieved
with low dose cisplatin compared to radiotherapy alone. So
far, there are only few reports on eYcacy and toxicity of low
dose cisplatin in radiochemotherapy for advanced HNSCC
(Hoebers et al. 2007; Jeremic et al. 2004; Jeremic and Mili-
cic 2008). Therefore, the purpose of this study was to evalu-
ate the toxicity in patients treated with this regimen for
locally advanced HNSCC either in the primary or adjuvant
situation in our department.
Methods and patients
From October 2003 to October 2006, all stage III/IVA/B
HNSCC patients treated in our department (primary or
adjuvant) were designated to receive concomitant cisplatin
6m g / m 2 on each radiotherapy day. No other cisplatin regi-
mens were used in our department during the respective
time period as patients, who were not able to receive cis-
platin due to a reduced creatinine clearance (·60 ml/min),
which was determined in every case before starting treat-
ment, were either selected to receive radiotherapy alone or
radiotherapy plus cetuximab in the primary situation. In
summary, 50 patients with locally advanced HNSCC
received concomitant radiochemotherapy with cisplatin
6m g / m 2 on each radiotherapy day in the respective time
period and therewith qualiWed for inclusion in the presented
study. All tumors were histologically determined as squa-
mous cell carcinoma (41 histologic grade 2 and 9 grade 3).
Forty-eight patients were males and two females, patients
age ranged from 43 to 80 years (median 61 years). Tumors
were localized as follows: oral cavity (6), oropharynx (29),
hypopharynx (7), and larynx (8). Disease was staged
according to the Union Internationale Contre le Cancer/
American Joint Committee on Cancer (UICC/AJCC) crite-
ria. Eight patients were in stage III, 35 patients were in
stage IVA, and 7 patients were in stage IVB. Thereby, in 2
patients the primary tumor was staged as T1, in 7 patients
as T2, in 15 patients as T3, and in 26 patients as T4. In sum-
mary, 43 patients presented with histologically proven pos-
itive cervical lymph nodes (6 patients N1, 30 patients N2,
and 7 patients N3). One day before the start of radiochemo-
therapy, the hemoglobin level was determined in each
patient, and its median was 8.9 mmol/l (13.9 g/dl) [range
6–11.5 mmol/l (9.3–17.9 g/dl)]. Four male patients pre-
sented with an anemia grade 1 according to the CTC score
before radiochemotherapy. These patients received blood
preservations to correct anemia before starting treatment.
Pretreatment characteristics of patients entered in study are
concluded in Table 1.
Initial examinations before treatment included medical
history, clinical ENT (ear-nose-throat) examination (magnify-
ing laryngoscopy, upper bronchoscopy, esophagoscopy,
ear-nose-throat endoscopy) with biopsies in potential
mucosal primary sites, complete blood counts, biochemical
analysis including creatinine clearance, electrocardiogram,
chest X-rays, abdominal ultrasound, and CT scans of the
thorax and the head and neck with contrast medium.
A total of 32 patients underwent curative surgery as a
primary treatment followed by adjuvant radiochemotherapy
up to a total dose of 64 Gy. Twenty-Wve of these patients
had histologically proven involved lymph nodes; extracap-
sular extension of lymph nodes was detected in six of these
patients. Eighteen inoperable patients were treated with pri-
mary radiochemotherapy to a total dose of 70 Gy. Thereby,
all patients received conventional fractionated 3-D confor-
mal external beam radiotherapy (2 Gy per fraction, Wve
times a week, no alternative fractionation schemes like
hyperfractionation were applied in our patient population).
The Wrst phase delivered a dose of 50 Gy to the primary
tumor and associated nodal drainage sites. Subsequently, a
boost was applied: In the primary setting, the boost
included the primary tumor and macroscopic involved
lymph node areas to a total dose of 70 Gy. In the adjuvant
situation, the boost was applied to the primary tumor region
and tributary lymph node regions including such lymph
nodes with extranodal spread to a total dose of 64 Gy.
Treatment was delivered with a Varian Clinac 600 C/D
accelerator (Varian, Palo Alto, CA, USA). The prescribed
Table 1 Pretreatment characteristics of patients entered in study
Characteristic No. patients (%)
Gender
Male 48 (96)
Female 2 (4)
Tumor localization
Oral cavity 6 (12)
Oropharynx 29 (58)
Hypopharynx 7 (14)
Larynx 8 (16)
Stage
III 8 (16)
IVA 35 (70)
IVB 7 (14)
Histologic grade
10  ( 0 )
2 41 (82)
39  ( 1 8 )
Hemoglobin level before treatment
>8.32 mmol/l (>13.9 g/dl) 23 (54)
<8.32 mmol/l (<13.9 g/dl) 27 (46)
Surgery
Yes 38 (76)
No 12 (24)J Cancer Res Clin Oncol (2009) 135:961–967 963
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dose was deWned in accordance with the International Com-
mission on Radiation Units and Measurement Report
(International Commission on Radiation Units and Mea-
surements Prescribing, recording and reporting photon
beam therapy. ICRU report No. 50, Bethesda, MD: ICRU
1993). Simultaneous chemotherapy was given as follows to
all patients in the study: Intravenous infusion of cisplatin
6m g / m 2 was combined with 1l NaCl with facultative antie-
metic medication on every radiotherapy day. Radiotherapy
was applied after a minimum of 3 h following chemother-
apy.
Toxicity was monitored weekly during radiochemother-
apy and every second week following therapy until disap-
pearance of acute toxicity. Subsequently, chronic toxicity
was monitored at least quarterly. Toxicity was classiWed
according to the CTC score for acute (Trotti et al. 2000)
and according to the LENT scoring system for chronic
toxicity (Rubin et al. 1995).
After radiochemotherapy, remission was evaluated by
clinical ENT-examination (ear-nose-throat endoscopy,
magnifying laryngoscopy, whenever necessary upper bron-
choscopy, and esophagoscopy) and a computed tomogra-
phy with contrast medium. Complete remission was deWned
as the complete regression of all tumor manifestations.
Afterwards, patients underwent quarterly clinical ENT-
examination, complete blood counts, biochemical analysis,
chest X-rays, abdominal ultrasound or a computed tomog-
raphy of the head and neck, if necessary. Biopsies were
taken from suspect Wndings to receive histological conWr-
mation of tumor growth.
Survival probabilities were calculated from the day of
histological diagnosis. The Kaplan–Meier product-limit
method was used to determine overall survival and loco-
regional control. Loco-regional control was deWned as the
absence of local or regional recurrence or progression
(Kaplan and Meier 1958). The impact of possible prognos-
tic factors was estimated by univariate analysis (log-rank
test) for gender, patient age, primary site, tumor stage, his-
tological grading, surgery, and preradiotherapeutic hemo-
globin levels. Statistical analyses were generated with the
program StatSoft, Inc. (2002) STATISTICA for windows
version 6.1.
Results
Toxicity
In summary, therapy was well tolerated. There were no
treatment-related deaths. Acute grade 3 sole mucositis/dys-
phagia was seen in 11 patients (22%), sole hematologic
toxicity ¸grade 3 occurred in 7 patients (14%) [5 leukope-
nia (3 of these patients with grade 4 toxicity), 1 patient
thrombopenia grade 3 and one patient leukopenia and
additionally anemia grade 3]. In another 4 patients (8%)
mucositis/dysphagia and hematologic toxicity grade 3 (2
leukopenia and 2 leukopenia and thrombopenia) was
observed. Thus, toxicity related changes of the therapy
schedule were infrequently necessary. Overall, 94% of our
patients received the intended dose of radiotherapy (in 2
patients receiving adjuvant treatment radiotherapy dose
was reduced from 64 to 60 Gy and from 64 to 62 Gy,
respectively and in one patient receiving primary radioche-
motherapy from 70 to 62 Gy). More than 80% of the
intended cumulative chemotherapy dose could be applied
in 90% of our patients (chemotherapy break for more than
one week was necessary in 8 patients, only). During follow-
up, high grade chronic toxicity (grade 3) was also infre-
quent and occurred in nine patients (18%), only (3 patients
xerostomia, 2 patients subcutaneous Wbrosis, 2 patients
lymphedema, and 2 patients subcutaneous Wbrosis and
lymphedema, respectively). No grade 4 chronic toxicity
was observed in our patients during follow-up.
Follow-up, response and overall survival/loco-regional 
relapse, loco-regional control and development of distant 
metastases
All patients, who underwent surgery in curative intent,
were at least macroscopically completely resected (28
patients R0-resection, 4 patients R1-resection). Complete
remission after primary radiochemotherapy was seen in 12/
18 patients (66%). In the other six patients, a partial remis-
sion was achieved. The median duration of follow-up was
24.2 months (range, 7.8–48.7 months). After this time, 38
patients (76%) remain alive. Death has occurred in 12
patients (24%); 9 of these died from tumor, and 3 died from
intercurrent disease (secondary primary tumor, pulmonary
embolism and one not known). Collectively, the 2- and 3-
year overall survival rates were 72.7 and 67.1%, respec-
tively. Loco-regional relapse (recurrence after complete or
progress after partial remission) occurred in ten patients (in
7 patients after adjuvant and 3 patients after primary radio-
chemotherapy); the median time to relapse was 9 months
(range 0.8–13.9). In nine patients, the initial site of relapse
was local and in one patient regional. Distant metastases
occurred in two patients (one hepatic and one pulmonal), in
both cases not associated with a loco-regional recurrence.
Collectively, the 2- and 3-year loco-regional control rates
were 78%.
Prognostic factors
To evaluate the prognostic value of individual factors, uni-
variate subgroup analyses concerning gender, patient age,
primary site, tumor stage, histological grading, surgery, and964 J Cancer Res Clin Oncol (2009) 135:961–967
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preradiotherapeutic hemoglobin levels have been done.
Subgroup analysis of tumor stage (stage III versus stage
IVA/B) showed that disease stage III at the time of diagno-
sis is associated with a statistical signiWcant (P = 0.02)
higher 2- and 3-year year overall survival compared to the
patients staged IVA/B (100 vs. 65.3%, and 100 vs. 57%,
respectively). In contrast, subgroup analyses concerning
gender, patient age, primary site, histological grading, sur-
gery, and preradiotherapeutic hemoglobin levels showed no
statistically signiWcant inXuence on overall survival or
loco-regional control. Still, this may be due to the small
sample size.
Discussion
Toxicity of diVerent chemotherapy regimens used 
in combined conventional fractionated primary or adjuvant 
radiochemotherapy for locally advanced HNSCC
The data show that our radiochemotherapy regimen using
low dose cisplatin is associated with relatively low high
grade (¸grade 3) toxicity. Thus, 94% of the patients
received the intended dose of radiotherapy and in 90% of
the patients ¸80% of the intended cumulative chemother-
apy dose could be applied. Other common chemotherapy
regimens (cisplatin 100 mg/m2 on days 1, 22, and 43 of
radiotherapy, 50 mg/m2 weekly during radiotherapy, or
20 mg/m2 for 4 days in week 1 and 5 of radiotherapy) are
associated with equal or considerably more high grade
acute toxicity: As shown in Table 2, the incidence of
¸grade 3 mucositis/dysphagia/hematologic toxicity in
these studies varies from 41 to 89%. High acute toxicity
may reduce quality of life in patients, and toxicity related
changes of the therapy concept may be necessary which,
however, may adversely inXuence prognosis. For example,
Bernier et al. (2004) described 2004 that the third cycle of
their chemotherapy (cisplatin 100 mg/m2 on days 1, 22, and
43 of radiotherapy) could be administered on time without
delay in only 49% of their patients.
Our data are in accordance with other studies using
daily low dose cisplatin in radiochemotherapy for locally
advanced HNSCC: Jeremic et al. (2004) and Hoebers
et al. (2007) also demonstrated that concurrent normo-
fractionated chemoradiation with daily low dose cisplatin
for advanced head and neck cancer patients is feasible and
eVective. Thereby, Jeremic et al. (2004) reported similar
data concerning toxicity compared to our study, Hoebers
et al. (2007), however, describe higher amounts (Table 2).
Additionally, Zuur et al. (2008) considered this treatment
scheme as a relatively safe protocol with respect to
ototoxicity.
Our data show a 2-year/3-year overall survival rate of
72.7%/67.1%, and a 2-year/3-year loco-regional-control
rate of 78%, respectively. However, as both, patients with
surgery and postoperative radiochemotherapy and
patients with radiochemotherapy alone as deWnitive treat-
ment are regarded, conclusions concerning oncological
eYcacy in comparison to the literature cannot be drawn
from the data.
EYcacy and toxicity of hyperfractionated and/or 
accelerated radio- or radiochemotherapy regimens 
for primary treatment of inoperable locally advanced 
HNSCC
Whereas in the adjuvant situation conventional fraction-
ated radiotherapy is the standard approach, overall sur-
vival and loco-regional control may be improved by
alternative fractionation like acceleration or hyperfrac-
tionation when using radiotherapy as primary therapy for
inoperable advanced HNSCC: It has been shown that
hyperfractionation with moderate dose escalation leads to
a signiWcant improvement of loco-regional control and
overall survival if radiation therapy is used as single
modality. In contrast, accelerated radiation therapy alone,
especially when given as split course radiation schedule,
does not increase overall survival (Budach et al. 2006).
However, no evidence proofs that hyperfractionation is
better compared to conventional fractionation if chemo-
therapy is given concomitantly (Welz et al. 2007). Fur-
thermore, it has to be considered that alternative
fractionation is associated with higher acute toxicity and
may lead to toxicity related changes of the therapy con-
cept resulting in negative impact on prognosis. Poten-
tially, daily low dose cisplatin is appropriate to reduce
acute toxicity in hyperfractionated radiotherapy without
compromising tumor control compared to regimens using
higher single doses of cisplatin for radiosensitizing. In
summary, despite hundreds of clinical trials in patients
with advanced disease, there is no absolute consensus
about patient selection for altered fraction regimens, type
of chemo-radiotherapy association, radiation or chemo-
therapy dose schedule (Corvo 2007).
Conclusion
We found concurrent chemoradiation with daily low dose
cisplatin to be feasible with advantage of low acute and
chronic toxicity. Therefore, use of low dose cisplatin
should be evaluated in future clinical trials testing conven-
tional or alternative fractionated radiotherapy for locally
advanced HNSCC.J Cancer Res Clin Oncol (2009) 135:961–967 965
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